Citations

Clear

6273 citation(s) found for "To, Andrew".

Is Aortic Valve Leaflet Morphology Predictive of Outcome in Pediatric Aortic Valve Stenosis?
Bowman, Jessica, Cao, Yumei , Tweddell, James S., Simpson, Pippa , Cetta, Frank , Pelech, Andrew N. , Bowman, Jessica L, Loomba, Rohit , Dearani, Joseph A.

Mayo Clinic

Congenital Heart Disease | July 29, 2015 | Volume: 10 | Issue: 6 | Pages: 552-560

10.1111/chd.12278 | PMID 26219421 Get It

Network-Based Integration of GWAS and Gene Expression Identifies a HOX -Centric Network Associated with Serous Ovarian Cancer Risk
Kar, Siddhartha , Lawrenson, Kate , Aben, Katja K.H. , Antonenkova, Natalia, Chenevix‐Trench, Georgia , Study, on behalf of the Australian Cancer, Group, and on behalf of the Australian Ovarian Cancer Study, Baker, Helen , Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Campbell, Ian , Carty, Karen , Chang‐Claude, Jenny , Chen, Y. Ann , Chen, Zhihua , Cunningham, Julie M. , Dansonka‐Mieszkowska, Agnieszka , Dicks, Ed , Dörk, Thilo , Eccles, Diana , Easton, Douglas F. , Edwards, Robert P., Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Giles, Graham G. , Glasspool, Rosalind , Goode, Ellen L. , Goodman, Marc T. , Grownwald, Jacek, Harrington, Patricia, Harter, Philipp , Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Estrid , Høgdall, Claus , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , Jensen, Allan , Ji, Bu‐Tian , Kjær, Susanne K. , Kelemen, Linda E. , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Krakstad, Camilla , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lee, Alice W. , Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Liang, Dong , Lissowska, Jolanta , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, Valerie , McLaughlin, John R., McNeish, Iain A. , Menon, Usha , Moysich, Kirsten B., Narod, Steven A., Nedergaard, Lotte , Ness, Roberta B., Odunsi, Kunle , Olson, Sara H. , Orlow, Irene , Oršulić, Sandra , Weber, Rachel Palmieri , Pearce, Celeste Leigh, Pelttari, Liisa M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Pike, Malcolm C., Ramus, Susan J. , Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B. , Rzepecka, Iwona K. , Salvesen, Helga B., Schildkraut, Joellen M. , Schwaab, Ira, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Sucheston‐Campbell, Lara, Tangen, Ingvild L. , Teo, Soo‐Hwang , Terry, Kathryn L. , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anne M. van , Nieuwenhuysen, Els Van , Vergote, Ignace , Vierkant, Robert A. , Wang‐Gohrke, Shan , Walsh, Christine , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Woo, Yin Ling , Wu, Xifeng , Wu, Anna H. , Zheng, Wei , Sellers, Thomas A. , Monteiro, Álvaro N.A. , Freedman, Matthew L., Gayther, Simon A. , Lu, Karen H. , Lambrechts, Diether , Tyrer, Jonathan P. , Li, Qiyuan , Anton‐Culver, Hoda , Study, on behalf of the Australian Cancer, Group, and on behalf of the Australian Ovarian Cancer Study, Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Hildebrandt, Michelle A.T. , Paul, James , Karlan, Beth Y. , Lu, Karen, McLaughlin, John R., Modugno, Francesmary , Nevanlinna, Heli , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rosen, Barry P. , Rudolph, Anja , Shu, Xiao‐Ou , Siddiqui, Nadeem , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Pharoah, Paul D.P. , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , Kjaer, Susanne K , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Monteiro, Alvaro N , Moysich, Kirsten , Orlow, Irene , Lissowska, Jolanta , Campbell, Ian G , Southey, Melissa C , Glasspool, Rosalind , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Zheng, Wei , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 24, 2015 | Volume: 24 | Issue: 10 | Pages: 1574-1584

10.1158/1055-9965.epi-14-1270 | PMID 26209509 Get It

Abstract Background: Genome-wide association studies (GWAS) have so far reported 12 loci associated with serous epithelial ovarian cancer (EOC) risk. We hypothesized that some of these loci function through nearby transcription factor (TF) genes and that putative target genes of these TFs as identified by coexpression may also be enriched for additional EOC risk associations. Methods: We selected TF genes within 1 Mb of the top signal at the 12 genome-wide significant risk loci. Mutual information, a form of correlation, was used to build networks of genes strongly coexpressed with each selected TF gene in the unified microarray dataset of 489 serous EOC tumors from The Cancer Genome Atlas. Genes represented in this dataset were subsequently ranked using a gene-level test based on results for germline SNPs from a serous EOC GWAS meta-analysis (2,196 cases/4,396 controls). Results: Gene set enrichment analysis identified six networks centered on TF genes (HOXB2, HOXB5, HOXB6, HOXB7 at 17q21.32 and HOXD1, HOXD3 at 2q31) that were significantly enriched for genes from the risk-associated end of the ranked list (P < 0.05 and FDR < 0.05). These results were replicated (P < 0.05) using an independent association study (7,035 cases/21,693 controls). Genes underlying enrichment in the six networks were pooled into a combined network. Conclusion: We identified a HOX-centric network associated with serous EOC risk containing several genes with known or emerging roles in serous EOC development. Impact: Network analysis integrating large, context-specific datasets has the potential to offer mechanistic insights into cancer susceptibility and prioritize genes for experimental characterization. Cancer Epidemiol Biomarkers Prev; 24(10); 1574–84. ©2015 AACR.
The safety of vasopressor-induced hypertension in subarachnoid hemorrhage patients with coexisting unruptured, unprotected intracranial aneurysms
Reynolds, Matthew R. , Buckley, Robert T., Indrakanti, Santoshi S. , Turkmani, Ali , Oh, Gerald, Crobeddu, Emanuela, Fargen, Kyle M , Amin‐Hanjani, Sepideh , Zipfel, Gregory J. , Ahmadieh, Tarek Y. El , Naidech, Andrew M. , Amin-Hanjani, Sepideh , Lanzino, Giuseppe , Hoh, Brian L. , Bendok, Bernard R. , Fargen, Kyle M

Mayo Clinic

Journal of Neurosurgery | July 24, 2015 | Volume: 123 | Issue: 4 | Pages: 862-871

10.3171/2014.12.jns141201 | PMID 26207606 Get It

OBJECT Vasopressor-induced hypertension (VIH) is an established treatment for patients with aneurysmal subarachnoid hemorrhage (SAH) who develop vasospasm and delayed cerebral ischemia (DCI). However, the safety of VIH in patients with coincident, unruptured, unprotected intracranial aneurysms is uncertain. METHODS This retrospective multiinstitutional study identified 1) patients with aneurysmal SAH and 1 or more unruptured, unprotected aneurysms who required VIH therapy (VIH group), and 2) patients with aneurysmal SAH and 1 or more unruptured, unprotected aneurysms who did not require VIH therapy (non-VIH group). All patients had previously undergone surgical or endovascular treatment for the presumed ruptured aneurysm. Comparisons between the VIH and non-VIH patients were made in terms of the patient characteristics, clinical and radiographic severity of SAH, total number of aneurysms, number of ruptured/unruptured aneurysms, aneurysm location/size, number of unruptured and unprotected aneurysms during VIH, severity of vasospasm, degree of hypervolemia, and degree and duration of VIH therapy. RESULTS For the VIH group (n = 176), 484 aneurysms were diagnosed, 231 aneurysms were treated, and 253 unruptured aneurysms were left unprotected during 1293 total days of VIH therapy (5.12 total years of VIH therapy for unruptured, unprotected aneurysms). For the non-VIH group (n = 73), 207 aneurysms were diagnosed, 93 aneurysms were treated, and 114 unruptured aneurysms were left unprotected. For the VIH and non-VIH groups, the mean sizes of the ruptured (7.2 ± 0.3 vs 7.8 ± 0.6 mm, respectively; p = 0.27) and unruptured (3.4 ± 0.2 vs 3.2 ± 0.2 mm, respectively; p = 0.40) aneurysms did not differ. The authors observed 1 new SAH from a previously unruptured, unprotected aneurysm in each group (1 of 176 vs 1 of 73 patients; p = 0.50). Baseline patient characteristics and comorbidities were similar between groups. While the degree of hypervolemia was similar between the VIH and non-VIH patients (fluid balance over the first 10 days of therapy: 3146.2 ± 296.4 vs 2910.5 ± 450.7 ml, respectively; p = 0.67), VIH resulted in a significant increase in mean arterial pressure (mean increase over the first 10 days of therapy relative to baseline: 125.1% ± 1.0% vs 98.2% ± 1.2%, respectively; p < 0.01) and systolic blood pressure (125.6% ± 1.1% vs. 104.1% ± 5.2%, respectively; p < 0.01). CONCLUSIONS For small, unruptured, unprotected intracranial aneurysms in SAH patients, the frequency of aneurysm rupture during VIH therapy is rare. The authors do not recommend withholding VIH therapy from these patients.
Chromosomes at Work: Organization of Chromosome Territories in the Interphase Nucleus
Fritz, Andrew J. , Martin‐Buley, Lori A., Wijnen, André J. van , Zaidi, Sayyed K. , Imbalzano, Anthony N. , Lian, Jane B. , Stein, Janet L. , van Wijnen, Andre J, Barutcu, A. Rasim , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Biochemistry | July 20, 2015 | Volume: 117 | Issue: 1 | Pages: 9-19

10.1002/jcb.25280 | PMID 26192137 Get It

ABSTRACTThe organization of interphase chromosomes in chromosome territories (CTs) was first proposed more than one hundred years ago. The introduction of increasingly sophisticated microscopic and molecular techniques, now provide complementary strategies for studying CTs in greater depth than ever before. Here we provide an overview of these strategies and how they are being used to elucidate CT interactions and the role of these dynamically regulated, nuclear‐structure building blocks in directly supporting nuclear function in a physiologically responsive manner. J. Cell. Biochem. 117: 9–19, 2016. © 2015 Wiley Periodicals, Inc.
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Korecka, Magdalena , Figurski, Michal, Toledo, Jon B. , Blennow, Kaj , Waligórska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly , Dean, Robert A., Vanderstichele, Hugo, Petersen, Ronald C. , Aisen, Paul , Saykin, Andrew J. , Weiner, Michael W. , Trojanowski, John Q. , Shaw, Leslie M. , Initiative, Alzheimer's Disease Neuroimaging, Kang, Ju‐Hee , Zetterberg, Henrik , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J

Mayo Clinic

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 772-791

10.1016/j.jalz.2015.05.003 | PMID 26194312 Get It

AbstractIntroductionWe describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.MethodsReview publications authored or coauthored by ADNI Biomarker core faculty and selected non‐ADNI studies to deepen the understanding and interpretation of CSF Aβ1–42, t‐tau, and p‐tau181 data.ResultsCSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non‐ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies.DiscussionFurther studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease‐modifying therapeutic trials.
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Weiner, Michael W. , Veitch, Dallas P. , Aisen, Paul, Cairns, Nigel J., Cedarbaum, Jesse M. , Donohue, Michael , Harvey, Danielle, Jack, Clifford R. , Jagust, William J. , Morris, John C. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Thompson, Paul M. , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Harvey, Danielle , Beckett, Laurel , Green, Robert C. , Harvey, Danielle, Toga, Arthur W. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Thompson, Paul M , Morris, John C , Donohue, Michael C , Harvey, Danielle J

Mayo Clinic

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 865-884

10.1016/j.jalz.2015.04.005 | PMID 26194320 Get It

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post‐traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data‐sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public‐private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.
Effects of lubricant and autologous bone marrow stromal cell augmentation on immobilized flexor tendon repairs
Zhao, Chunfeng , Ozasa, Yasuhiro , Shimura, Haruhiko , Reisdorf, Ramona L., Thoreson, Andrew R. , Jay, Gregory D. , Moran, Steven L. , An, Kai‐Nan, Amadio, Peter C. , An, Kai‐Nan

Mayo Clinic

Journal of Orthopaedic Research | July 16, 2015 | Volume: 34 | Issue: 1 | Pages: 154-160

10.1002/jor.22980 | PMID 26177854 Get It

ABSTRACTThe purpose of the study was to test a novel treatment that carbodiimide‐derivatized‐hyaluronic acid‐lubricin (cd‐HA‐lubricin) combined cell‐based therapy in an immobilized flexor tendon repair in a canine model. Seventy‐eight flexor tendons from 39 dogs were transected. One tendon was treated with cd‐HA‐lubricin plus an interpositional graft of 8 × 105 BMSCs and GDF‐5. The other tendon was repaired without treatment. After 21 day of immobilization, 19 dogs were sacrificed; the remaining 20 dogs underwent a 21‐day rehabilitation protocol before euthanasia. The work of flexion, tendon gliding resistance, and adhesion score in treated tendons were significantly less than the untreated tendons (p < 0.05). The failure strength of the untreated tendons was higher than the treated tendons at 21 and 42 days (p < 0.05). However, there is no significant difference in stiffness between two groups at day 42. Histologic analysis of treated tendons showed a smooth surface and viable transplanted cells 42 days after the repair, whereas untreated tendons showed severe adhesion formation around the repair site. The combination of lubricant and cell treatment resulted in significantly improved digit function, reduced adhesion formation. This novel treatment can address the unmet needs of patients who are unable to commence an early mobilization protocol after flexor tendon repair. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:154–160, 2016.
Treatment of Axis Body Fractures
Kepler, Christopher K., Fleischman, Andrew N. , Traynelis, Vincent C. , Patel, Alpesh A. , Dekutoski, Mark B. , Wood, Kirkham B. , Schroeder, Gregory D. , Aarabi, Bizhan , Okonkwo, David O. , Fehlings, Michael G. , Shaffrey, Christopher I. , Kwon, Brian K. , Kepler, Christopher K. , Vaccaro, Alexander R. , Harrop, James Shields , Bransford, Richard Jackson , Arnold, Paul M. , Nassr, Ahmad , Fehlings, Michael G

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | July 11, 2015 | Volume: 30 | Issue: 10 | Pages: 442-456

10.1097/bsd.0000000000000309 | PMID 29176489 Get It

Study Design: Evidence-based systematic review. Objectives: To define the optimal treatment of fractures involving the C2 body, including those with concomitant injuries, based upon a systematic review of the literature. Summary of Background Data: Axis body fractures have customarily been treated nonoperatively, but there are some injuries that may require operative intervention. High-quality literature is sparse and there are few class I or class II studies to guide treatment decisions. Materials and Methods: A literature search was conducted using PubMed (MEDLINE), Cochrane Central Register of Controlled Trials, and Scopus (EMBASE, MEDLINE, COMPENDEX). The quality of literature was rated according to a grading tool developed by the Center for Evidence-based Medicine. Operative and nonoperative treatment of axis body fractures were compared using fracture bony union as the primary outcome measure. As risk factors for nonunion were not consistently reported, cases were analyzed individually. Results: The literature search identified 62 studies, of which 10 were case reports which were excluded from the analysis. A total of 920 patients from 52 studies were included. The overall bony union rate for all axis body fractures was 91%. Although the majority of fractures were treated nonoperatively, there has been an increasing trend toward operative intervention for Benzel type III (transverse) axis body fractures. Nearly 76% of axis body fractures were classified as type III fractures, of which 88% united successfully. Nearly all Benzel type I and type II axis body fractures were successfully treated nonoperatively. The risk factors for nonunion included: a higher degree of subluxation, fracture displacement, comminution, concurrent injuries, delay in treatment, and older age. Conclusions: High rates for fracture union are reported in the literature for axis body fractures with nonoperative treatment. High-quality prospective studies are required to develop consensus as to which C2 body fractures require operative fixation.
Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Johnatty, Sharon E. , Kar, Siddhartha , Beesley, Jonathan, Lu, Yi , Gao, Bo , Fasching, Peter A. , Hein, Alexander , Ekici, Arif B. , Beckmann, Matthias W. , Lambrechts, Diether , Nieuwenhuysen, Els Van , Vergote, Ignace , Lambrechts, Sandrina, Rossing, Mary Anne, Chang‐Claude, Jenny , Ness, Roberta B., Moysich, Kirsten B., Levine, Douglas A. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Lubiński, Jan , Jakubowska, Anna , Brinton, Louise A. , Lissowska, Jolanta , Wentzensen, Nicolas , Song, Honglin , Rhenius, Valerie , Campbell, Ian , Eccles, Diana , Sieh, Weiva , Whittemore, Alice S. , McGuire, Valerie , Rothstein, Joseph H. , Sutphen, Rebecca , Gayther, Simon A. , Menon, Usha , Ramus, Susan J. , Pearce, Celeste Leigh, Pike, Malcolm C. , Wu, Anna H. , Kupryjańczyk, Jolanta , Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Śpiewankiewicz, Beata, Goodman, Marc T. , Carney, Michael E., Thompson, Pamela J., Heitz, Florian , Schwaab, Ira, Harter, Philipp , Pisterer, Jacobus, Hillemanns, Peter , Group, on behalf of the AGO Study, Walsh, Christine M. , Lester, Jenny, Oršulić, Sandra , Winham, Stacey J. , Earp, Madalene A. , Fogarty, Zachary C. , Høgdall, Estrid , Jensen, Allan , Cunningham, Julie M. , Vierkant, Robert A. , Schildkraut, Joellen M. , Iversen, Edwin S., Terry, Kathryn L. , Orlow, Irene , Bean, Yukie T., Høgdall, Claus , Lundvall, Lene, McNeish, Iain A. , Paul, James, Carty, Karen , Glasspool, Rosalind , Sellers, Thomas , Kennedy, Catherine J. , Chiew, Yoke-Eng , MacGregor, Stuart , Goode, Ellen L. , DeFazio, Anna , Webb, Penelope M. , Chenevix‐Trench, Georgia , Lambrechts, Diether , Earp, Madalene, Fazio, Anna de , Tyrer, Jonathan P. , Beesley, Jonathan, Doherty, Jennifer A. , Modugno, Francesmary , Gronwald, Jacek , Cybulski, Cezary , Anton‐Culver, Hoda , Ziogas, Argyrios , Gentry‐Maharaj, Aleksandra , Stram, Daniel O. , Wilkens, Lynne R. , Bois, Andreas du , Group, on behalf of the AGO Study, Karlan, Beth Y. , Lester, Jenny, Larson, Melissa C. , Kjær, Susanne K. , Fridley, Brooke L. , Cramer, Daniel W. , Bandera, Elisa V. , Pejovic, Tanja B. , Siddiqui, Nadeem , Berchuck, Andrew , Pharoah, Paul D.P. , Winham, Stacey J , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Moysich, Kirsten , Orlow, Irene , Lissowska, Jolanta , Campbell, Ian G , Glasspool, Rosalind , Kennedy, Catherine J , Fogarty, Zachary C , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Lu, Yi , MacGregor, Stuart , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Clinical Cancer Research | July 7, 2015 | Volume: 21 | Issue: 23 | Pages: 5264-5276

10.1158/1078-0432.ccr-15-0632 | PMID 26152742 Get It

Abstract Purpose: Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. Experimental Design: We analyzed approximately 2.8 million genotyped and imputed SNPs from the iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 European epithelial ovarian cancer (EOC) patients who underwent first-line treatment of cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 patients treated with ≥4 cycles of paclitaxel and carboplatin at standard doses. We evaluated the top SNPs in 4,434 EOC patients, including patients from The Cancer Genome Atlas. In addition, we conducted pathway analysis of all intragenic SNPs and tested their association with PFS and OS using gene set enrichment analysis. Results: Five SNPs were significantly associated (P ≤ 1.0 × 10−5) with poorer outcomes in at least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23), and rs6674079 (1q22), were located in long noncoding RNAs (lncRNAs) RP11-179A10.1, RP11-314O13.1, and RP11-284F21.8, respectively (P ≤ 7.1 × 10−6). ENCODE ChIP-seq data at 1q22 for normal ovary show evidence of histone modification around RP11-284F21.8, and rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, expression levels of which were reportedly associated with prognosis in another solid tumor. YAP1- and WWTR1 (TAZ)-stimulated gene expression and high-density lipoprotein (HDL)-mediated lipid transport pathways were associated with PFS and OS, respectively, in the cohort who had standard chemotherapy (pGSEA ≤6 × 10−3). Conclusions: We have identified SNPs in three lncRNAs that might be important targets for novel EOC therapies. Clin Cancer Res; 21(23); 5264–76. ©2015 AACR.
Longitudinal Ultrasound Curriculum Improves Long-Term Retention Among Internal Medicine Residents
Kelm, Diana J. , Ratelle, John T. , Azeem, Nabeel , Bonnes, Sara L. , Halvorsen, Andrew J. , Bhagra, Anjali , Oxentenko, Amy S.

Mayo Clinic

Journal of Graduate Medical Education | July 6, 2015 | Volume: 7 | Issue: 3 | Pages: 454-457

10.4300/jgme-14-00284.1 | PMID 26457155 Get It

ABSTRACT Background Point-of-care ultrasound is a rapidly evolving component of internal medicine (IM) residency training. The optimal approach for teaching this skill remains unclear. Objective We sought to determine whether the addition of a longitudinal ultrasound curriculum to a stand-alone workshop for ultrasound training improved knowledge retention in IM residents. Methods We conducted an observational cohort study from July to December 2013. All postgraduate year (PGY)-1 IM residents attended an ultrasound workshop during orientation. Ability to identify static images of ascites, kidney, thyroid, pleural fluid, inferior vena cava, and internal jugular vein was assessed immediately after the workshop. An ultrasound curriculum, including morning report and ultrasound rounds, was initiated during the inpatient medicine rotation. PGY-1 residents were randomly assigned to participate in the longitudinal curriculum. Six months later, we conducted a follow-up survey with all PGY-1 residents. Results Forty-eight PGY-1 residents (67%) completed the postworkshop test and the 6-month follow-up test. Of these, 50% (24 of 48) had participated in the ultrasound curriculum. Residents not exposed to the curriculum showed a decline in the identification of ascites, pleural effusion, and internal jugular vein at 6 months (P &lt; .05), whereas those who participated in the curriculum maintained their performance (P &lt; .05). Conclusions Six months after exposure to a longitudinal ultrasound curriculum, residents were more likely to correctly identify ultrasound images of ascites, kidney, and pleural effusion. The addition of a longitudinal ultrasound curriculum may result in improved knowledge retention in IM residents.